Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiobarbituric SCHEMBL31059040 | 0.83 | GSK3A (0.38) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| Thiobarbituric SCHEMBL16027 | 0.83 | — | — | |
| Thiobarbituric SCHEMBL8216351 | 0.80 | GSK3A (0.36) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| Thiobarbituric SCHEMBL2344775 | 0.80 | GSK3A (0.36) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| Thiobarbituric SCHEMBL2351184 | 0.80 | GSK3A (0.36) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| Thiobarbituric SCHEMBL7714190 | 0.76 | ALDH1A1 (0.42) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| Barbituric Acid SCHEMBL4726594 | 0.75 | ALDH1A1 (0.44) | ALDH1A1GSK3AGSK3BITGB3ITGB1 | |
| Thiobarbituric SCHEMBL144675 | 0.71 | ITGB3 (0.33) | ALDH1A1GSK3AGSK3BITGB3ITGB1 | |
| Biphenyl SCHEMBL5667075 | 0.71 | TDP2 (0.49) | ALDH1A1GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL8028070 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244234-A1 | POLYPEPTIDES AND METHODS FOR IMPROVING SKIN CONDITIONS | InterK Peptide Therapeutics Limited (AU) | 2023-09-20 | — | — | EP | disclosed |
| US-20220409510-A1 | Polypeptides And Methods For Improving Skin Conditions | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2022-12-29 | — | — | US | disclosed |
| WO-2022099364-A1 | POLYPEPTIDES AND METHODS FOR IMPROVING SKIN CONDITIONS | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2022-05-19 | — | — | WO | disclosed |
| EP-3938374-A2 | PHENYLPROPANOID SACCHARIDE ESTERS, METHODS AND USES THEREOF | UNIVERSIDADE NOVA DE LISBOA (PT) | 2022-01-19 | — | — | EP | disclosed |
| US-20210380639-A1 | Activating Agents | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| CN-111592405-B | Organic water-soluble fertilizer capable of resisting wheat dry hot air and powdery mildew as well as preparation and application thereof | 山东省农业科学院农业资源与环境研究所 | 2021-11-09 | — | — | CN | disclosed |
| CN-113166205-A | Polypeptides and methods for improving skin conditions | 英特肽治疗有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3794015-A1 | ACTIVATING AGENTS | InterK Peptide Therapeutics Limited (AU) | 2021-03-24 | — | — | EP | disclosed |
| CN-112368293-A | Activating agent | 英特肽治疗有限公司 | 2021-02-12 | — | — | CN | disclosed |
| WO-2020183442-A2 | PHENYLPROPANOID SACCHARIDE ESTERS, METHODS AND USES THEREOF | UNIVERSIDADE NOVA DE LISBOA (PT) | 2020-09-17 | — | — | WO | disclosed |
| EP-2147673-A1 | Modulation of prostaglandin/cyclooxygenase metabolic pathways | Hunter-Fleming Limited (GB) | 2010-01-27 | — | — | EP | disclosed |
| CN-101594861-A | The adjusting of prostaglandin/cyclooxygenase metabolic pathways | HUNTER FLEMING LTD (GB) | 2009-12-02 | — | — | CN | disclosed |
| US-20090197811-A1 | ORALLY ADMINISTERED PEPTIDES TO IMPROVE OR PREVENT HEPATIC FIBROSIS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009012400-A2 | ORALLY ADMINISTERED PEPTIDES TO IMPROVE OR PREVENT HEPATIC FIBROSIS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-01-22 | — | — | WO | disclosed |
| CN-101208083-A | Treatment with statin and Omega-3 fatty acids and a combination product thereof | RELIANT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-101098690-A | Omega-3 fatty acids and dyslipidemic agent for lipid therapy | RELIANT PHARMACEUTICALS INC (US) | 2008-01-02 | — | — | CN | disclosed |
| US-20060205826-A1 | Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions | KEMIN FOODS, L.C. | 2006-09-14 | — | — | US | disclosed |
| US-6906059-B2 | Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances | SOLVAY PHARMACEUTICALS (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20030040512-A1 | Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances | SOLVAY PHARMACEUTICALS (DE) | 2003-02-27 | — | — | US | disclosed |
| US-20020065258-A1 | Non-estrogenic estradiol derivative compounds with antioxidative activity | DROESCHER PETER (DE) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065258-A1 | Non-estrogenic estradiol derivative compounds with antioxidative activity | CYP19A1, HSD17B11, SULT2A1 | ALDH1A1 292/4885GSK3A 1977/4885GSK3B 2060/4885 |
| US-20030040512-A1 | Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances | TNNC1, MB, FABP3 | ALDH1A1 151/4885GSK3A 2490/4885GSK3B 2732/4885 |
| US-20210380639-A1 | Activating Agents | LCK, CD69, NFATC1 | ALDH1A1 4293/4885GSK3A 554/4885GSK3B 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.